Many of these are improved by lifestyle changes (Box
INTRODUCTION

F or people identified as being at risk of cardiovascular disease (CVD), the degree or intensity of intervention is dictated by the predicted likelihood of a future coronary event. Assessment of cardiovascular risk factors is therefore essential so that individuals can be stratified as accurately as possible into 'very high', 'high' or 'moderate-to-low' risk categories. The high-risk category (Box 1) includes all those with established cardiovascular, cerebrovascular or peripheral vascular disease, or with diabetes; a subset of these regarded as 'very high' risk are targeted for more aggressive intervention (Box 2). Appropriate screening can also identify asymptomatic individuals who are considered to be at high risk because they have multiple risk factors. Although there is some variation between guidelines in the definition of 'high cardiovascular risk', this term usually refers to patients whose 10-year risk of an atherosclerotic coronary event (eg myocardial infarction) is ≥20% (see previous article in this series 'Screening and identifying at-risk patients'). This article aims to provide practitioners with a concise guide to the management of high-risk patients based on recommendations from six of the most up-todate clinical practice guidelines for prevention of CVD (Box 3)
. [1] [2] [3] [4] [5] [6] [7] We refer non-English speakers to the French Health Products Safety Agency and the Spanish local guidelines. 8, 9 
TREATMENT GOALS IN HIGH-RISK PATIENTS
Once a patient' s high-risk status has been established, it is important to address all risk factors amenable to intervention including:
• Cigarette 
HDL-C and triglycerides
Some guidelines recommend total cholesterol:HDL-C ratio as an alternative target benchmark for intervention (Table 2). Low levels of HDL-C and
Box 2: Very high-risk patients
Guideline (see Box 3 for full reference)
Goal or treatment recommended? Table 5 (Table 4) . Figure 1 ). 13 
Reduce overweight
Weight reduction is an important goal in overweight or obese high-risk individuals. Bodyweight is most readily quantified as body mass index (BMI;
Individuals with BMI values ≥25 kg/m 2 should receive counselling and help in achieving bodyweight reduction. Cardiovascular risk is also influenced by the regional distribution of body fat, and abdominal fat is particularly detrimental. Patients with abdominal obesity (commonly defined as a waist circumference >102 cm in American men, >88 cm in American women) should be encouraged to lose weight, regardless of BMI. Weight loss is difficult to achieve and maintain, but must involve a combination of dietary modification and increased physical activity. In high-risk patients, the recommended level of physical exertion should be based on the results of a comprehensive clinical evaluation. Inclusion of an exercise test in this evaluation is discretionary. Achieving a 5% reduction in bodyweight is a good first step.
Improve diet
For patients at high risk of CVD, dietary modification has three main aims: i) to lower LDL-C ii) to increase HDL-C
ii) to allow the patient to achieve an optimal bodyweight. Table 5 summarises the core dietary recommendations made by the guidelines. [1] [2] [3] [4] [5] [6] [7] 14 In addition to providing detailed recommendations on lipid intake, the guidelines recommend minimum daily intakes of dietary constituents believed to provide protection against CVD, such as omega-3 fatty acids and fruits and vegetables.
Physical activity
A minimum of 30 minutes three times a week of physical activity (eg rapid walk) should be recommended.
Reduce thrombotic risk
With few exceptions, acute cardiovascular events are caused by formation of an intra-arterial thrombus.
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